In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer-Reference-Cited by-同舟云学术

In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer

Published:2024 Issue:4 Volume:15 Page:1362-1380
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Carvalho Luísa¹²,de Lima Fábio Pedroso³,Cerqueira Mónica¹²,Silva Ana¹²,Pontes Olívia¹²,Oliveira-Pinto Sofia¹²,Guerreiro Sara¹²⁴^ORCID,Costa Marta D.¹²^ORCID,Granja Sara¹²⁴,Maciel Patrícia¹²^ORCID,Longatto-Filho Adhemar¹²⁵⁶,Baltazar Fátima¹²^ORCID,Proença Fernanda³,Costa Marta¹²^ORCID

Affiliation:

1. Life and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal

2. ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal

3. Department of Chemistry, University of Minho, Campus of Gualtar, Braga, Portugal

4. Department of Pathological, Cytological and Thanatological Anatomy, School of Health, Polytechnic Institute of Porto, 4200-072 Porto, Portugal

5. Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil

6. Medical Laboratory of Medical Investigation (LIM) 14, Department of Pathology, Medical School, University of São Paulo, São Paulo, Brazil

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and the limited therapeutic options show poor efficacy in patients, associated to severe side effects and development of resistance.

Funder

Fundação para a Ciência e a Tecnologia

Universidade do Minho

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00682D

Reference53 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer

3. Clinical implications of the intrinsic molecular subtypes of breast cancer

4. Intrinsic cancer subtypes-next steps into personalized medicine

5. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes